文献速递乳腺癌放疗

放射治疗诱导乳腺癌的分子改变

Molecular Changes in Breast Cancer Induced by Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-18

本综述聚焦乳腺癌放射治疗(RT)诱导的分子、遗传和蛋白质组学改变,涵盖免疫系统、免疫原性及远隔效应、肿瘤缺氧、乳腺癌分型、分子异质性与可塑性等方面,指出仅凭临床亚型不足以解释RT反应差异,多种肿瘤微环境与免疫因素及RT剂量分割方案共同影响RT结局。

要点

  • 乳腺癌RT反应差异不能用临床亚型单独解释,肿瘤微环境、免疫系统、RT剂量分割和内在异质性均参与。
  • RT可在临床成功的同时改变肿瘤细胞表型、免疫原性和微环境, preclinical研究已显示此潜力。
  • 作者认为个性化抗癌治疗方案可能对克服放射抵抗至关重要。

核心结论

  • 尽管抗癌治疗近期取得进展,肿瘤抵抗仍是重大挑战;随着分析技术深入揭示乳腺癌及其治疗反应的复杂分子机制,个性化抗癌治疗方案可能对克服放射抵抗至关重要。

研究设计与样本

  • 综述:检索并回顾当前文献,重点纳入近期在分子、遗传和蛋白质组学层面阐明肿瘤相关放射诱导分子改变的研究。

主要发现

  • RT在临床上是成功的治疗方式,但临床前研究显示其有改变肿瘤细胞表型、免疫原性和周围微环境的潜力,可能改变癌细胞行为并导致RT反应显著差异。
  • 乳腺癌放射诱导分子改变已从免疫系统、免疫原性及远隔效应、肿瘤缺氧、乳腺癌分类与亚型、分子异质性、分子可塑性等多个生理角度进行探讨。
  • 仅凭乳腺癌临床亚型不足以解释RT反应或放射抵抗的差异。
  • 肿瘤微环境和免疫系统的多个组分、给予的RT剂量与分割方案、放射诱导的旁效应以及肿瘤内在生理与异质性均参与最终RT结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Breast cancer treatments are based on prognostic clinicopathologic features that form the basis for therapeutic guidelines. Although the utilization of these guidelines has decreased breast cancer-associated mortality rates over the past three decades, they are not adequate for individualized therapy. Radiation therapy (RT) is the backbone of breast cancer treatment. Although a highly successful therapeutic modality clinically, from a biological perspective, preclinical studies have shown RT to have the potential to alter tumor cell phenotype, immunogenicity, and the surrounding microenvironment, potentially changing the behavior of cancer cells and resulting in a significant variation in RT response. This review presents the recent advances in revealing the complex molecular changes induced by RT in the treatment of breast cancer and highlights the complexities of translating this information into clinically relevant tools for improved prognostic insights and the revelation of novel approaches for optimizing RT. METHODS AND MATERIALS: Current literature was reviewed with a focus on recent advances made in the elucidation of tumor-associated radiation-induced molecular changes across molecular, genetic, and proteomic bases. This review was structured with the aim of providing an up-to-date overview over the very broad and complex subject matter of radiation-induced molecular changes and radioresistance, familiarizing the reader with the broader issue at hand. RESULTS: The subject of radiation-induced molecular changes in breast cancer has been broached from various physiological focal points including that of the immune system, immunogenicity and the abscopal effect, tumor hypoxia, breast cancer classification and subtyping, molecular heterogeneity, and molecular plasticity. It is becoming increasingly apparent that breast cancer clinical subtyping alone does not adequately account for variation in RT response or radioresistance. Multiple components of the tumor microenvironment and immune system, delivered RT dose and fractionation schedules, radiation-induced bystander effects, and intrinsic tumor physiology and heterogeneity all contribute to the resultant RT outcome. CONCLUSIONS: Despite recent advances and improvements in anticancer therapies, tumor resistance remains a significant challenge. As new analytical techniques and technologies continue to provide crucial insight into the complex molecular mechanisms of breast cancer and its treatment responses, it is becoming more evident that personalized anticancer treatment regimens may be vital in overcoming radioresistance.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sheva K, Roy Chowdhury S, Kravchenko-Balasha N, et al. Molecular Changes in Breast Cancer Induced by Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024. PMID: 38508467. doi:10.1016/j.ijrobp.2024.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。